Vanguard Personalized Indexing Management
FATE icon

Vanguard Personalized Indexing Management’s Fate Therapeutics FATE Stock Holding History

Vanguard Personalized Indexing Management’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$136K Buy
50,416
+392
+0.8% +$725 ﹤0.01% 1997
2026
Q1 		$60K Sell
50,024
-923
-2% -$1.12K ﹤0.01% 2027
2025
Q4 		$50.1K Sell
50,947
-13,296
-21% -$16K ﹤0.01% 1881
2025
Q3 		$80.9K Sell
64,243
-7,121
-10% -$7.68K ﹤0.01% 1848
2025
Q2 		$79.9K Buy
71,364
+28,268
+66% +$32.9K ﹤0.01% 1770
2025
Q1 		$34K Buy
43,096
+28,324
+192% +$34.7K ﹤0.01% 1715
2024
Q4 		$24.4K Buy
14,772
+821
+6% +$2.07K ﹤0.01% 1754
2024
Q3 		$48.8K Sell
13,951
-826
-6% -$3.21K ﹤0.01% 1679
2024
Q2 		$48.5K Buy
14,777
+1,195
+9% +$5.23K ﹤0.01% 1587
2024
Q1 		$99.7K Buy
13,582
+1,225
+10% +$7.58K ﹤0.01% 1520
2023
Q4 		$46.2K Sell
12,357
-1,997
-14% -$4.71K ﹤0.01% 1520
2023
Q3 		$30.4K Buy
+14,354
New +$47.6K ﹤0.01% 1431
2022
Q3 		– Sell
-10,100
Closed -$250K – 1251
2022
Q2 		$250K Sell
10,100
-334
-3% -$9.21K 0.01% 1042
2022
Q1 		$405K Buy
10,434
+6,402
+159% +$248K 0.02% 908
2021
Q4 		$236K Buy
4,032
+225
+6% +$12.8K 0.01% 943
2021
Q3 		$226K Buy
3,807
+1,326
+53% +$104K 0.02% 886
2021
Q2 		$215K Buy
+2,481
New +$200K 0.02% 869

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Personalized Indexing Management's FATE Position: Q2 2026 in Review

Vanguard Personalized Indexing Management increased its Fate Therapeutics (FATE) stake by 0.78% in Q2 2026, buying an estimated $725 and bringing the position to 50,416 shares worth $136K. The position accounts for ﹤0.01% of the portfolio, ranked #1997.

Vanguard Personalized Indexing Management first reported a position in FATE in Q2 2021 and has held it in 17 quarters since. The position peaked at $405K in Q1 2022. 156 funds tracked by Wall St. Rank hold FATE as of Q2 2026.

  • Vanguard Personalized Indexing Management held 50,416 shares of Fate Therapeutics worth $136K as of Q2 2026.
  • Vanguard Personalized Indexing Management bought 392 Fate Therapeutics shares in Q2 2026, an estimated $725.
  • Fate Therapeutics made up ﹤0.01% of Vanguard Personalized Indexing Management's portfolio in Q2 2026, its #1997 holding.
  • Vanguard Personalized Indexing Management first reported a position in Fate Therapeutics in Q2 2021 and has held it in 17 quarters since.
  • Vanguard Personalized Indexing Management's Fate Therapeutics position peaked at $405K in Q1 2022.
  • 156 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2026.

Based on Vanguard Personalized Indexing Management's 13F filing for Q2 2026, filed 11 Aug 2026.